MD/PhD student Anna Aristarkhova receives grant to study visual loss in multiple sclerosis patients
MD/PhD student Anna Aristarkhova received a predoctoral fellowship award from the NIH to research the mechanisms underlying visual loss in multiple sclerosis.
Read more
, ,
Oct 29, 2025
UMass Chan Medical School scientists to assess gene editing technologies for treating frontotemporal dementia
UMass Chan scientists have received funding to explore gene editing technologies for treating frontotemporal dementia.
Read more
, ,
May 15, 2025
UMass Chan licenses RNA-based treatment for fragile X syndrome to QurAlis Corporation
UMass Chan licenses potential RNA-based treatment for fragile X syndrome to QurAlis Corporation.
Read more
, ,
Mar 14, 2025
UMass Chan faculty present translational research at BRIDGE Fund Innovation Showcase
UMass Chan supports translational research from faculty with internal funding mechanism.
Read more
, ,
Jun 25, 2024
UMass Chan, QurAlis Corporation partnership expands on biomedical research by Joel Richter
UMass Chan Medical School and QurAlis Corporation, a clinical-stage biotechnology company investigating treatments for amyotrophic lateral sclerosis, frontotemporal dementia and other neurodegenerative and neurological diseases, have formed a collaboration to investigate an antisense oligonucleotide technology for the potential treatment of fragile X syndrome.
Read more
, ,
Mar 4, 2024
UMass Chan scientists receive $2.3 million from Rett Syndrome Research Trust for new research
Rett syndrome is a rare geneticneurological disorder that occurs primarily in girls, eventually robbing them of the ability to speak, walk or use their hands, among other devastating effects.
Read more
, ,
Oct 25, 2023
UMass Chan helps ‘Crack the Code’ at biotech career day in Worcester
Representatives from UMass Chan presented on several topics and career paths, including RNA Therapeutics Institute, ScienceLive, community and government relations, diversity and inclusion and media and arts in sciences.
Read more
, ,
Jul 3, 2023
Antisense therapy restores fragile X protein production in human cells
An antisense therapy developed by Joel D. Richter, PhD, Sneha Shah, PhD, and Jonathan K. Watts, PhD, at UMass Chan Medical School and Elizabeth Berry-Kravis, MD, PhD, at RUSH University Medical Center, restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.
Read more
, ,
Apr 12, 2023
UMass Chan scientists deliver siRNA therapy to lung
A multidisciplinary team of UMass Chan scientists has developed a technology for delivering siRNA molecules locally to lung tissue, providing the first evidence of a platform capable of delivering chemically modified siRNAs to the lungs nasally and achieving robust genetic silencing.
Read more
, ,
Feb 2, 2023
PhD candidate awarded NIH Kirschstein Award for research on Rett syndrome
PhD candidate David Keener has received a National Institutes of Health grant to fund his research project on Rett syndrome, a genetic neurodevelopmental disease generally diagnosed in girls ages 6 to 18 months.
Read more
, ,
Mar 1, 2022
UMass Chan ALS paper selected for STAT Madness
Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and colleagues showed the ability to suppress mutant forms of the ALS gene known as C9ORF72 in a single-patient pilot study. The paper reporting the results is part of the 2022 STAT News STAT Madness competition.
Read more
, ,
Dec 23, 2021
UMass Chan clinical trial shows antisense oligonucleotide safely suppresses mutant ALS gene in pilot human study
Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and colleagues have shown the ability to suppress mutant forms of an ALS gene in a single-patient pilot study.
Read more
, ,
Apr 7, 2021
Erik Sontheimer co-leading efforts to develop gene editing toolkit by NIH Somatic Cell Genome Editing Consortium
Six UMass Medical School scientists are among the members of the National Institutes of Health’s Somatic Cell Genome Editing Consortium to publish a paper in Nature outlining the program’s goals.
Read more
, ,
Dec 18, 2020
Inside the new mRNA vaccines for COVID-19
The new vaccines by Pfizer/BioNTech and Moderna use messenger RNA to stimulate the immune system to protect against COVID-19. These vaccines are the first of their kind and researchers at UMass Medical School are among the leading RNA biologists in the world.
